Alanine aminotransferase (ALT) testing is one of the most widely performed liver function assays in clinical laboratories, providing essential information about hepatocellular injury and overall liver health. This technical article explores ALT detection principles, sample requirements, analytical methods, reference ranges, and clinical applications for laboratory professionals and clinicians.
Technical Overview
Alanine aminotransferase (ALT, EC 2.6.1.2), formerly known as serum glutamic pyruvic transaminase (SGPT), is a pyridoxal phosphate-dependent enzyme that catalyzes the reversible transfer of an amino group from L-alanine to alpha-ketoglutarate, yielding pyruvate and L-glutamate. Although ALT is present in most tissues, it is highly concentrated in hepatocyte cytoplasm, making it the most liver-specific enzyme routinely measured in clinical chemistry. When hepatocytes are damaged or destroyed, ALT is released into the bloodstream, causing serum activity to rise, often before clinical symptoms appear. Quantitative ALT measurement therefore serves as a sensitive and specific biomarker for hepatocellular injury, liver disease screening, therapeutic drug monitoring, and evaluation of conditions such as viral hepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and drug-induced liver injury.
Testing Samples
Serum
Serum collected from a plain tube or serum separator tube (SST) is the preferred specimen for ALT determination. Venous blood should be drawn following standard phlebotomy procedures, allowed to clot completely for 20 to 30 minutes at room temperature, and centrifuged to obtain a clear, hemolysis-free serum sample. Serum ALT is stable for up to 3 days at 2 to 8 degrees Celsius and for several months when frozen at minus 20 degrees Celsius or below, with minimal loss of activity.
Plasma
Plasma anticoagulated with lithium heparin or EDTA is acceptable on most automated analyzers, provided the assay system has been validated for that matrix. Citrate, fluoride, and oxalate anticoagulants are generally not recommended because they dilute the sample through liquid anticoagulation and may interfere with enzyme kinetics. Plasma must be separated from cells promptly to avoid leakage of intracellular enzymes.
Sample Handling and Interference Considerations
- Hemolysis significantly elevates ALT results because erythrocytes contain measurable enzyme activity; mildly to moderately hemolyzed specimens should be rejected or flagged according to laboratory policy.
- Icterus and lipemia may cause spectral interference at 340 nm and should be assessed, ideally using automated hemolysis-index and lipemia-index checks.
- Sample tubes should be filled to the correct ratio to maintain anticoagulant concentration when plasma is used.
- Repeat freeze-thaw cycles should be avoided, as they can degrade enzymatic activity.
- Recent strenuous exercise, intramuscular injections, and muscle trauma may transiently elevate ALT and should be documented during specimen collection.
Testing Items
The core analytical item is the enzymatic activity of ALT in serum or plasma, reported in units per liter (U/L), also expressed as international units per liter (IU/L) or microkatals per liter. Typical adult reference intervals are approximately 7 to 56 U/L, although many laboratories and professional societies now recommend sex-specific upper limits of normal, commonly around 29 to 33 U/L for adult males and 19 to 25 U/L for adult females, based on population studies. Because reference limits vary with age, sex, body mass index, methodology, and local population characteristics, each laboratory must establish or verify its own intervals. Interpretive reporting should consider the degree of elevation, the AST-to-ALT ratio (De Ritis ratio), and correlation with other liver markers such as AST, alkaline phosphatase, gamma-glutamyl transferase, bilirubin, and albumin.
Testing Methods
IFCC Continuous-Monitoring (Kinetic UV) Method
The internationally recognized reference method follows the recommendation of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), optimized for measurement at 37 degrees Celsius. In the coupled reaction, ALT converts L-alanine and alpha-ketoglutarate into pyruvate and L-glutamate. The pyruvate is then reduced to lactate by lactate dehydrogenase (LDH) with simultaneous oxidation of NADH to NAD. The rate of decrease in NADH absorbance, monitored kinetically at 340 nm (secondary wavelength typically 405 to 700 nm), is directly proportional to ALT catalytic activity. Many current reagent formulations instead couple glutamate formation to glutamate dehydrogenase via malate dehydrogenase, an alternative that avoids interference from endogenous pyruvate.
Pyridoxal-5-Phosphate Supplementation
Modern reagents often include pyridoxal-5-phosphate (P5P), the active coenzyme of ALT, to fully activate apoenzyme forms of the enzyme. This is particularly important in patients with vitamin B6 deficiency, chronic alcohol use, or uremia, where unsupplemented assays may underestimate true ALT activity.
Analytical Performance and Quality Control
- Assay linearity typically extends from 3 to 500 U/L or higher; specimens exceeding the linear range must be diluted and reanalyzed with results multiplied by the dilution factor.
- Liquid stable ready-to-use reagents are available for most open automated chemistry analyzers, with onboard stability commonly 30 days at 2 to 8 degrees Celsius after opening.
- Two-level quality control materials, calibrated against IFCC-reference-procedure-assigned values, should be run at least daily, with acceptance criteria defined by Westgard rules or equivalent statistical QC schemes.
- Laboratories should participate in external quality assessment and proficiency testing programs and maintain traceability to the IFCC reference measurement system.
Point-of-Care and Alternative Platforms
Dry-slide chemistry systems, portable enzymatic analyzers, and rapid point-of-care test devices enable ALT measurement in settings such as blood donor screening, clinical trials, occupational health programs, and field epidemiological surveys. These platforms trade some analytical flexibility for speed and reduced sample volume, and their results must be harmonized with central laboratory methods.
Applications
- Detection and grading of hepatocellular injury in acute and chronic viral hepatitis, including monitoring of hepatitis B and hepatitis C therapy.
- Screening and staging support for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in metabolic risk populations.
- Assessment of alcoholic liver disease, typically in combination with AST and the AST-to-ALT ratio.
- Safety monitoring of hepatotoxic medications such as isoniazid, methotrexate, statins, and checkpoint-inhibitor immunotherapy.
- Evaluation of drug-induced liver injury (DILI) and herbal or dietary supplement toxicity using Hy's law criteria alongside bilirubin.
- Preoperative and pre-employment health screening, insurance medical examinations, and blood donor eligibility assessment.
- Longitudinal surveillance in patients with cirrhosis, autoimmune hepatitis, hemochromatosis, and Wilson disease.
- Epidemiological research and public health surveillance of liver disease burden in populations.
FAQ
What does a high ALT level mean?
Elevated ALT indicates hepatocellular damage or leakage of the enzyme from liver cells. Mild elevations, up to two to three times the upper limit of normal, are frequently associated with fatty liver disease, alcohol consumption, obesity, or medication effects. Marked elevations exceeding ten times the upper limit suggest acute hepatitis, ischemic hepatopathy, toxic injury, or other severe hepatic insults and warrant urgent clinical evaluation.
Can ALT be low, and is that a problem?
Low ALT activity is generally benign but can occur in chronic kidney disease, vitamin B6 deficiency, zinc deficiency, advanced cirrhosis with reduced functional liver mass, and in long-term hemodialysis patients. Persistently low values in high-risk individuals may occasionally prompt further nutritional or hepatic assessment.
Do I need to fast before an ALT test?
Fasting is not strictly required for ALT alone, but because ALT is usually ordered as part of a comprehensive metabolic or liver panel that includes glucose and lipids, an 8-to-12-hour fast is commonly requested. Alcohol and strenuous exercise should be avoided for at least 24 hours before sampling to prevent spurious elevations.
How quickly can results be obtained?
On automated chemistry analyzers, the kinetic ALT assay completes within approximately 8 to 15 minutes per sample, and most hospital laboratories report results the same day. Point-of-care systems can deliver quantitative results in under 15 minutes from a fingerstick or small venous sample.
What follow-up tests are recommended when ALT is abnormal?
Abnormal ALT results are typically followed by repeat measurement, AST, GGT, alkaline phosphatase, bilirubin fractionation, complete blood count, hepatitis B and C serology, and, when indicated, ferritin, ceruloplasmin, autoimmune markers, or abdominal imaging to establish the underlying etiology.